Ensysce Biosciences Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price
Summary
Ensysce Biosciences received a Nasdaq delisting notice due to its stock trading below $1.00, initiating a 180-day compliance period to avoid potential delisting.
Key Events
-
Nasdaq Delisting Notice Received
On February 25, 2026, Ensysce Biosciences received a notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
-
180-Day Compliance Period Initiated
The company has 180 calendar days, until August 24, 2026, to regain compliance by having its common stock close at or above $1.00 for at least ten consecutive business days.
-
Potential Delisting Consequences
Failure to regain compliance could lead to delisting, which would make it more difficult to trade securities, potentially cause a material price decline, and impair the company's ability to raise capital.
Analysis
Ensysce Biosciences, a micro-cap company, has received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement. While the company has 180 days to regain compliance, failure to do so could lead to delisting, which would severely impair its ability to raise capital and maintain investor interest. This event highlights significant financial and operational challenges, posing a material risk to the company's public market viability. Investors should monitor the company's efforts to regain compliance closely.
At the time of this filing, ENSC was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.31 to $5.72. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.